Ultra-sensitive NGS-based liquid biopsy technology in CDx

QIAGEN and Sysmex Inostics have recently announced a global alliance for the development and commercialization of cancer companion diagnostics (CDx). The partnership capitalizes on Sysmex Inostics’ Plasma-Safe-SeqS (SafeSEQ), an ultra-sensitive next generation sequencing (NGS) liquid biopsy technology and leverages QIAGEN’s experience in developing and commercializing companion diagnostics.

Learn more about:
  • Embracing opportunity through the QIAGEN-Sysmex partnership
  • The Power of SafeSEQ: Technology and performance overview
  • Realizing the clinical value of ultra-sensitive technology
Play the webinar preview
Speak with an expert
Discover how QIAGEN’s NGS CDx capabilities can advance your CDx development and global commercialization.
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm